"Uterine Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the UTERUS.
Descriptor ID |
D014594
|
MeSH Number(s) |
C04.588.945.418.948 C13.351.500.852.762 C13.351.937.418.875
|
Concept/Terms |
Uterine Neoplasms- Uterine Neoplasms
- Neoplasms, Uterus
- Neoplasm, Uterus
- Uterus Neoplasm
- Uterus Neoplasms
- Neoplasms, Uterine
- Neoplasm, Uterine
- Uterine Neoplasm
Cancer of Uterus- Cancer of Uterus
- Uterus Cancers
- Cancer of the Uterus
- Uterus Cancer
- Cancer, Uterus
- Cancers, Uterus
- Uterine Cancer
- Cancer, Uterine
- Cancers, Uterine
- Uterine Cancers
|
Below are MeSH descriptors whose meaning is more general than "Uterine Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Uterine Neoplasms".
This graph shows the total number of publications written about "Uterine Neoplasms" by people in this website by year, and whether "Uterine Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1996 | 1 | 0 | 1 |
1997 | 1 | 1 | 2 |
2000 | 1 | 1 | 2 |
2001 | 1 | 0 | 1 |
2002 | 2 | 0 | 2 |
2003 | 2 | 1 | 3 |
2004 | 2 | 0 | 2 |
2005 | 4 | 0 | 4 |
2006 | 7 | 0 | 7 |
2007 | 3 | 0 | 3 |
2008 | 3 | 0 | 3 |
2009 | 3 | 0 | 3 |
2010 | 4 | 2 | 6 |
2011 | 4 | 1 | 5 |
2012 | 4 | 1 | 5 |
2013 | 6 | 0 | 6 |
2014 | 6 | 0 | 6 |
2015 | 9 | 0 | 9 |
2016 | 9 | 4 | 13 |
2017 | 10 | 2 | 12 |
2018 | 13 | 1 | 14 |
2019 | 4 | 0 | 4 |
2020 | 15 | 0 | 15 |
2021 | 12 | 0 | 12 |
2022 | 17 | 0 | 17 |
2023 | 20 | 0 | 20 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Uterine Neoplasms" by people in Profiles.
-
Uterine Fibroid Prevalence in a Predominantly Black, Chicago-Based Cohort. Int J Environ Res Public Health. 2024 Feb 14; 21(2).
-
Survivin-Sodium Iodide Symporter Reporter as a Non-Invasive Diagnostic Marker to Differentiate Uterine Leiomyosarcoma from Leiomyoma. Cells. 2023 12 13; 12(24).
-
Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach). Int J Mol Sci. 2023 Nov 04; 24(21).
-
Current and Emerging Treatment Options for Uterine Fibroids. Drugs. 2023 Dec; 83(18):1649-1675.
-
Disparities in Gynecologic Cancers. Cancer J. 2023 Nov-Dec 01; 29(6):343-353.
-
Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 Feb; 230(2):237.e1-237.e11.
-
Fibroids and Fertility. Obstet Gynecol Clin North Am. 2023 Dec; 50(4):663-675.
-
The combination of natural compounds Crila and epigallocatechin gallate showed enhanced antiproliferative effects on human uterine fibroid cells compared with single treatments. F S Sci. 2023 11; 4(4):341-349.
-
LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023 12; 229(6):662.e1-662.e25.
-
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids - current roles and future perspectives. Expert Opin Pharmacother. 2023 Sep-Dec; 24(16):1799-1809.